Sun Pharma Advanced Research

Regd Office: Sun Pharma Advance

Akota Road, Akota, Vadodara 390 02
CIN No. : L73100GJ2006PLC047837 We

Part I

Statement of Unaudited Financial Results for the Quarter/Year ended March

Particulars

Income
Income from Operations
Total Income
Expenditure
Cost of Materials Consumed
Employee Benefits Expense
Clinical Trials and Professional Charges
Depreciation Expense
License and Fees
Other Expenses
Total Expenses
Profit / (Loss) from Operations before Other Income and Finance Costs
Other Income
Profit / (Loss) before Finance Costs
Finance Costs
Profit / (Loss) before Tax
Tax Expense
Profit / (Loss) for the period / year
Paid-up Equity Share Capital - Face Value ` 1 each
Reserves excluding Revaluation Reserve
Earnings Per Share of ` 1 each in ` (Basic and Diluted)

Part II

Select information for the Quarter/Year ended March 31, 2015

Particulars

Particulars of Shareholding
Public Shareholding
No. of Equity Shares
Percentage of Shareholding
Promoters and Promoter Group Shareholding
a)
Pledged / Encumbered
No. of Equity Shares
Percentage of Equity Shares (as a % of the total shareholding of promoter and promoter group)

Percentage of Equity Shares (as a % of the total share capital of the Company)
b)

Non-encumbered
No. of Equity Shares
Percentage of Equity Shares (as a % of the total shareholding of promoter and promoter group)
Percentage of Equity Shares (as a % of the total share capital of the Company)

Investor Complaints
Pending at the beginning of the quarter
Received during the quarter
Disposed of during the quarter
Remaining unresolved at the end of the quarter
Notes :
1

Statement of Assets and Liabilities

Particulars

A
i

ii

EQUITY AND LIABILITIES

Shareholders' Funds
(a)
Share Capital
(b)
Reserves and Surplus
Non-current Liabilities
(a)
Long-term Borrowings
(b)
Deferred Tax Liabilities (Net)
(c)
Other Long-term Liabilities
(d)
Long-term Provisions

iii Current Liabilities

(a)
Short-term Borrowings
(b)
Trade Payables
(c)
Other Current Liabilities
(d)
Short-term Provisions
TOTAL - EQUITY AND LIABILITIES
B
i

ii

ASSETS
Non-current Assets
(a)
Fixed Assets
(b)
Long-term Loans and Advances
(c)
Other Non-current Assets
Current Assets
(a)
Current Investments
(b)
Trade Receivables
(c)
Cash and Cash Equivalents
(d)
Short-term Loans and Advances
(e)
Other Current Assets

TOTAL - ASSETS
2

The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board o

The Company has only one reportable business segment namely 'Pharmaceutical Research & Development'.

Status of Utilisation of rights issue proceeds:

Particulars

Any Research and Development activities / expenses *

Repayment of identified loans availed from Group Entities
General corporate purposes
Issue expenses
Funds utilised
Un-utilised rights issue proceeds

Calls unpaid
Total
Previous Year Total

* Revised from 'Pharmaceutical research and development activities - Clinical trials' in terms of resolution passed by s
the Company's business of Pharmaceutical Research and Development, the actual utilisation of the funds varies from
Previous year figures are in brackets
5

The Company has adopted the useful lives of fixed assets as indicated in Part C of Schedule II of the Companies A
Affairs. Consequently, the depreciation charge for the quarter ended March 31, 2015 is higher by ` 70 Lakhs and for t

Figures for the previous periods / year have been regrouped / reclassified, wherever considered necessary.

Figures for the quarter ended March 31, 2015 and March 31, 2014 are balancing figures between the audited figures
of the respective financial years.

Mumbai, May 5, 2015

Advanced Research Company Limited

e: Sun Pharma Advanced Research Centre,

ota, Vadodara 390 020. Tel. No.0265-2330815
GJ2006PLC047837 Web Site : www.sunpharma.in

/Year ended March 31, 2015

Quarter ended
31.03.2015
Unaudited
Refer Note 7

31.12.2014
Unaudited

Year ended
31.03.2014
Unaudited
Refer Note 7

31.03.2015
Audited

4,270
4,270

3,128
3,128

4,257
4,257

15,574
15,574

306
1,190
2,775
178
70
729
5,248
(978)
43
(935)
5
(940)
(940)

325
1,150
2,880
180
13
558
5,106
(1,978)
93
(1,885)
6
(1,891)
(1,891)

140
837
1,787
89
1,372
591
4,816
(559)
264
(295)
20
(315)
(64)
(251)

1,010
4,579
11,061
724
140
2,293
19,807
(4,233)
303
(3,930)
22
(3,952)
(3,952)

2,367

2,367

2,367

(0.40)

(0.80)

(0.11)

2,367
7,613
(1.67)

d March 31, 2015

Quarter ended
31.03.2015

31.12.2014

Year ended
31.03.2014

31.03.2015

77,811,251
32.87

77,811,251
32.87

77,811,251
32.87

77,811,251
32.87

1,162,066

675,000

675,000

1,162,066

0.73

0.42

0.42

0.73

0.49

0.29

0.29

0.49

157,731,130

158,218,196

158,218,196

157,731,130

99.27

99.58

99.58

99.27

66.64

66.84

66.84

66.64

2
2
-

As at 31.03.2015
Audited

2,367
7,613
327
8
237
40
2,701
898
77

As at 31.03.2014
Audited

9,980

2,367
11,563

572

382
16
148

3,716

82
2,974
758
64

14,268

6,682
1,262
30
1,989
1,734
2,543
28

7,974

6,525
760
57

6,294

650
2,800
656
6,494
412

14,268
approved by the Board of Directors at their respective meetings held on May 5, 2015.

& Development'.

Total Projected
utilisation

Projected
utilisation up to
31.03.2015

Actual utilisation
upto 31.03.2015

Projected
utilisation for the
year 31.03.2015

` in Lakhs

` in Lakhs

` in Lakhs

` in Lakhs

10,298
(10,298)
6,100
(6,100)
3,256
(3,256)
170
(170)
19,824
(19,824)
19,824
19,824

10,298
(5,139)
6,100
(6,100)
3,256
(3,256)
170
(170)
19,824
(14,665)
(5,159)
19,824
(19,824)
19,824

10,302
(5,142)
6,100
(6,100)
3,256
(3,256)
152
(152)
19,810
(14,650)
(5,158)
19,810
(19,808)
14
(16)
19,824

5,159
(4,376)
5,159
(4,376)
5,159
(4,376)
5,159

(19,824)

(19,824)

(19,824)

(4,376)

of resolution passed by shareholders at the Annual General Meeting held on July 30, 2013. Given the highly unpredictable nature of
n of the funds varies from the projections.

ule II of the Companies Act, 2013 and amendment thereto vide notification dated August 29, 2014 issued by Ministry of Corporate
r by ` 70 Lakhs and for the year ended March 31, 2015 is higher by ` 323 Lakhs.

red necessary.

ween the audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter
By order of the Board

Chairman and Managing Director

` in Lakhs
Year ended
31.03.2014
Audited

16,703
16,703
801
4,040
5,274
357
1,441
1,798
13,711
2,992
1,000
3,992
560
3,432
400
3,032
2,367
11,563
1.28

Year ended
31.03.2014

77,811,251
32.87

675,000
0.42

0.29
158,218,196
99.58
66.84

` in Lakhs
As at 31.03.2014
Audited

13,930

546

3,878
18,354

7,342

11,012

18,354

Actual utilisation
for the year ended
31.03.2015
` in Lakhs
5,160
(4,376)
5,160
(4,376)
5,160
(4,376)
784
(4,376)

e highly unpredictable nature of

sued by Ministry of Corporate

figures up to the third quarter

By order of the Board

Dilip S. Shanghvi
hairman and Managing Director